Pre-operative evaluation of ovarian mass: Risk of malignancy index

Journal of the College of Physicians and Surgeons Pakistan

Volumn 14, Issue 3, 2004, Pages 128-131

  Asif, Naveed ^a   Sattar, Abdus ^a   Dawood, Mirza Mohammad ^b   Rafi, Tariq ^a   Aamir, Muhammad ^a   Anwar, Masood ^c  

^a Peshawar Cantonment   (Pakistan)

^b FAUJI FOUNDATION HOSPITAL   (Pakistan)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (Pakistan)

Author keywords

Cancer associated antigen 125 (CA 125); Ovarian mass; Receiver operating characteristic (ROC) curve; Risk of malignancy index (RMI)

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; BENIGN TUMOR; CALCULATION; CANCER RISK; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; ECHOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CANCER; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY; AGE DISTRIBUTION; BLOOD; MIDDLE AGED; OVARY TUMOR; POSTMENOPAUSE; PREMENOPAUSE; RISK ASSESSMENT;

ADULT; AGE DISTRIBUTION; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 3142770350     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33.
2. Yiung RC, Decke DG, Wharton JT, Piver MS, Sindeler WF, Smith BK. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072-6.
3. Landis SH, Murray T, Bolen S, Wingo PA. Cancer statistics, 1988. CA Cancer J Clin 1998; 48: 6-29.
4. Murad A. Ovulation induction and ovarian tumours, the debate continues. J Pak Med Assoc 1998; 48: 353-6.
5. Ahmed N. Tumor markers - role in clinical oncology. Pak J Med Res 1993; 32: 310-4.
6. Gillis CR, Hole DJ, Still RM, Davis J, Kaye SB. Medical audit, cancer registration, and survival in ovarian cancer. Lancet 1991; 337: 611-2.
7. Seiden MV. Ovarian cancer. Oncologist 2001; 6: 327-32.
8. Schutter EM, Kenemans P, Sohn C, Kriston P, Crombash G, Westermann R, et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with ovarian mass: an international multicentric study. Cancer 1994; 74: 1398-1406.
9. Jacobs I, Stabile I, Bridges J, Kemsley P, Oram D. Multimodal approach to screening for ovarian cancer. Lancet 1988; 8: 268-71.
10. Fishman DA, Cohen L, Bozorgi K, Tamura R, Lurain JR. The role of ultrasound in detecting early ovarian carcinoma: the national ovarian cancer early detection programe. Medicamundi 2001; 45: 42-7.
11. Kehoe S, Selman T. Tumor markers in ovarian cancer. Hosp Med 2001; 62: 452-3.
12. Meden H, Fattahi-Meibodi A. CA 125 in benign gynecological conditions. Int J Biol Markers 1998; 13: 231-7.
13. Buamah P. Benign conditions associated with raised serum CA 125 concentration. J Surg Oncol 2000; 75: 264-5.
14. Mogenson O. CA 125 in ovarian cancer: advances and controversy. Clin Chem 1998; 7: 1379-80.
15. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynecol 1990; 97: 922-9.
16. National Committee for Clinical Laboratory Standards, Procedure for the collection of diagnostic blood specimens by venipuncture, 3rd ed. NCCLS Document H3-A3, 1991.
17. Bonfrer JMG. Technical evaluation of three second generation CA 125 assays. Eur J Clin Chem Clin Biochem 1994; 32: 201-7.
18. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell Scientific 1987.
19. Shultz EK. Selection and interpretation of laboratory procedures. In: Burtis CA, Ashwood ER, (edi). Tietz textbook of clinical chemistry. 3rd ed. Philadelphia: WB Saunders 1999; 310-19.
20. Zweig MH, Cambell G. Receiver operating curve (ROC) plots: a fudamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-77.
21. Gonzalez AG. Is the early diagnosis of ovarian cancer possible? Acta Ginecologica 2001; 58: 178-83.
22. Vuento MH, Stenman UH, Pirhinen JP, Makinen JI, Laippala PJ. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian cancer and endometrial cancer. Gynecol Oncol 1997; 64: 141-6.
23. Manjunath AP, Pratapkumar, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001; 81: 225-9.
24. Parvez T, Anwar MS. Diagnostic value of different tumor markers, our experience. J Coll Physincins Surg Pak 2000; 10: 418-20.
25. Maorgante G, la Marca A, Ditto A, De Leo V. Comparison of two malignancy risk indices based on serum CA 125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999; 106: 524-7.
26. Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993; 100: 927-31.
27. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996; 103: 826-31.
28. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk of malignancy index to evaluate potential ovarian cancers in local hospitals. Br J Obstet Gynaecol 1999; 93: 448-52.
29. Hagen B, Tingulstad S, Onsrud M, Moen M, Kiserud T, Eik-Nes S, et al. Pre-operative identification of malignancy among women with a pelvic mass. Evaluation of a risk index based on ultrasound findings, CA 125 in serum and menopausal status. Tidsskr-Nor-Laegeforen 1995; 115: 820-2.